[Federal Register Volume 82, Number 71 (Friday, April 14, 2017)]
[Notices]
[Page 17996]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-07593]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Health Resources and Services Administration
CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD
Prevention and Treatment
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) and the Health Resources and Services Administration
(HRSA) announce the following committee meeting.
Times and Dates: 8:30 a.m.-5:00 p.m., EDT, May 10, 2017; 8:30 a.m.-
3:00 p.m., EDT, May 11, 2017.
Place: CDC Corporate Square, Building 8, Conference Room 1-ABC, 8
Corporate Boulevard, Atlanta, Georgia 30329, Telephone: (404) 639-8317.
The meeting is also accessible by teleconference. Toll-free number 1-
877-603-4228, Participant code: 42598858.
Status: Open to the public, limited only by the space available.
The meeting room will accommodate approximately 100 people. Persons who
desire to make an oral statement, may request it at the time of the
public comment period on May 10, 2017 at 4:30 p.m., EDT. Public
participation and ability to comment will be limited to space and time
as it permits.
Purpose: This committee is charged with advising the Director, CDC
and the Administrator, HRSA, regarding activities related to prevention
and control of HIV/AIDS, Viral Hepatitis and other STDs, the support of
health care services to persons living with HIV/AIDS, and education of
health professionals and the public about HIV/AIDS, Viral Hepatitis and
other STDs.
Matters for Discussion: Agenda items include the following topics:
(1) HIV transmission risk in the context of viral suppression and
antiretroviral therapy (ART) use; (2) Update on Pre-Exposure
Prophylaxis (PrEP) utilization; (3) Vulnerable youth at risk for HIV,
STDs, hepatitis, substance use and other health outcomes; (4)
Eliminating hepatitis B and hepatitis C as public health threats in the
United States--Setting Goals and Taking Action; and (5) Updates from
Workgroups. Agenda items are subject to change as priorities dictate.
Contact Person for More Information: Margie Scott-Cseh, Centers for
Disease Control and Prevention, 1600 Clifton Road NE., Mailstop E-07,
Atlanta, Georgia 30329, telephone (404) 639-8317; Email: [email protected].
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register Notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2017-07593 Filed 4-13-17; 8:45 am]
BILLING CODE 4163-18-P